Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Mini-Review Article

Probiotics as a Therapeutic Approach in Colorectal Cancer

Author(s): Nafiseh Rahmani, Ghazaleh Pourali, Nayyerehalsadat Hosseini, Hamid Fiuji, Mina Maftooh, Seyed Mahdi Hassanian, Gordon A Ferns, Majid Khazaei* and Amir Avan*

Volume 23, Issue 10, 2023

Published on: 19 May, 2023

Page: [764 - 777] Pages: 14

DOI: 10.2174/1568009623666230413081513

Price: $65

conference banner
Abstract

Colorectal cancer (CRC) is a growing concern worldwide. In recent decades, the incidence of CRC has increased, and this has been attributed to changes in lifestyle. The lack of physical activity, smoking habits, and a diet high in red meat and fat and low in fiber are important aspects of these deleterious changes in lifestyle. The increase in the incidence of CRC has impelled researchers to investigate methods for preventing and treating CRC with greater efficacy and fewer complications. Probiotics are an attractive and potentially promising therapeutic approach. They have been evaluated by a large number of preclinical and clinical studies in recent years, and it has been found that they can play a role in the prevention, treatment, and management of complications of CRC. This review provides a concise summary of the mechanisms of action of probiotics. Furthermore, it focuses on the results of clinical and preclinical studies that evaluated probiotics' effects on CRC management. It also discusses the effects of different strains of probiotics and their combination in CRC treatment.

Keywords: Colorectal cancer, probiotics, prevention, treatment, complications, CRC management.

« Previous Next »
Graphical Abstract

[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
[http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID: 15761078]
[2]
World health organization. Estimated age-standardized incidence and mortality rates (World) in 2020, worldwide, both sexes, all ages (excl. NMSC). , 2020. Available from: https://gco.iarc.fr/today/online-analysis-multi
[3]
Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017, 66(4), 683-691.
[http://dx.doi.org/10.1136/gutjnl-2015-310912] [PMID: 26818619]
[4]
Siegel, R.L.; Torre, L.A.; Soerjomataram, I.; Hayes, R.B.; Bray, F.; Weber, T.K.; Jemal, A. Global patterns and trends in colorectal cancer incidence in young adults. Gut, 2019, 68(12), 2179-2185.
[http://dx.doi.org/10.1136/gutjnl-2019-319511] [PMID: 31488504]
[5]
Johnson, C.M.; Wei, C.; Ensor, J.E.; Smolenski, D.J.; Amos, C.I.; Levin, B.; Berry, D.A. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control, 2013, 24(6), 1207-1222.
[http://dx.doi.org/10.1007/s10552-013-0201-5] [PMID: 23563998]
[6]
Huxley, R.R.; Ansary-Moghaddam, A.; Clifton, P.; Czernichow, S.; Parr, C.L.; Woodward, M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological evidence. Int. J. Cancer, 2009, 125(1), 171-180.
[http://dx.doi.org/10.1002/ijc.24343] [PMID: 19350627]
[7]
Rawla, P.; Sunkara, T.; Barsouk, A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Gastroenterology Review/Przegląd Gastroenterologiczny,, 2019, 14(2), 89-103.
[http://dx.doi.org/10.5114/pg.2018.81072]
[8]
Wong, M.C.S.; Ding, H.; Wang, J.; Chan, P.S.F.; Huang, J. Prevalence and risk factors of colorectal cancer in Asia. Intest. Res., 2019, 17(3), 317-329.
[http://dx.doi.org/10.5217/ir.2019.00021] [PMID: 31085968]
[9]
Ahmed, S.; Johnson, K.; Ahmed, O.; Iqbal, N. Advances in the management of colorectal cancer: from biology to treatment. Int. J. Colorectal Dis., 2014, 29(9), 1031-1042.
[http://dx.doi.org/10.1007/s00384-014-1928-5] [PMID: 24953060]
[10]
Kishore, C.; Bhadra, P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur. J. Pharmacol., 2021, 893, 173819.
[http://dx.doi.org/10.1016/j.ejphar.2020.173819] [PMID: 33347822]
[11]
Florescu-Ţenea, R.M.; Kamal, A.M.; Mitruţ P.; Mitruţ R.; Ilie, D.S.; Nicolaescu, A.C.; Mogoantă L. Colorectal cancer: an update on treatment options and future perspectives. Curr. Health Sci. J., 2019, 45(2), 134-141.
[PMID: 31624639]
[12]
Biller, L.H.; Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA, 2021, 325(7), 669-685.
[http://dx.doi.org/10.1001/jama.2021.0106] [PMID: 33591350]
[13]
Passardi, A.; Canale, M.; Valgiusti, M.; Ulivi, P. Immune checkpoints as a target for colorectal cancer treatment. Int. J. Mol. Sci., 2017, 18(6), 1324.
[http://dx.doi.org/10.3390/ijms18061324] [PMID: 28635639]
[14]
Hendler, R.; Zhang, Y. Probiotics in the treatment of colorectal cancer. Medicines , 2018, 5(3), 101.
[http://dx.doi.org/10.3390/medicines5030101] [PMID: 30205429]
[15]
Williams, N.T. Probiotics. Am. J. Health Syst. Pharm., 2010, 67(6), 449-458.
[http://dx.doi.org/10.2146/ajhp090168] [PMID: 20208051]
[16]
Ouwehand, A.C.; Salminen, S.; Isolauri, E. probiotics: an overview of beneficial effects, in lactic acid bacteria: Genetics, metabolism and applications. Proceedings of the seventh Symposium on lactic acid bacteria: Genetics, metabolism and applications, the Netherlands., 2002, pp. 279-289.
[http://dx.doi.org/10.1007/978-94-017-2029-8_18]
[17]
Reid, G.; Jass, J.; Sebulsky, M.T.; McCormick, J.K. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev., 2003, 16(4), 658-672.
[http://dx.doi.org/10.1128/CMR.16.4.658-672.2003] [PMID: 14557292]
[18]
Górska, A.; Przystupski, D.; Niemczura, M.J.; Kulbacka, J. Probiotic bacteria: A promising tool in cancer prevention and therapy. Curr. Microbiol., 2019, 76(8), 939-949.
[http://dx.doi.org/10.1007/s00284-019-01679-8] [PMID: 30949803]
[19]
Lu, K.; Dong, S.; Wu, X.; Jin, R.; Chen, H. Probiotics in Cancer. Front. Oncol., 2021, 11, 638148.
[http://dx.doi.org/10.3389/fonc.2021.638148] [PMID: 33791223]
[20]
Zaharuddin, L.; Mokhtar, N.M.; Muhammad Nawawi, K.N.; Raja Ali, R.A. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol., 2019, 19(1), 131.
[http://dx.doi.org/10.1186/s12876-019-1047-4] [PMID: 31340751]
[21]
Xia, Y.; Yang, Z.; Chen, H.Q.; Qin, H.L. Effect of bowel preparation with probiotics on intestinal barrier after surgery for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 2010, 13(7), 528-531.
[PMID: 20658369]
[22]
Gianotti, L.; Morelli, L.; Galbiati, F.; Rocchetti, S.; Coppola, S.; Beneduce, A.; Gilardini, C.; Zonenschain, D.; Nespoli, A.; Braga, M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J. Gastroenterol., 2010, 16(2), 167-175.
[http://dx.doi.org/10.3748/wjg.v16.i2.167] [PMID: 20066735]
[23]
Kotzampassi, K.; Stavrou, G.; Damoraki, G.; Georgitsi, M.; Basdanis, G.; Tsaousi, G.; Giamarellos-Bourboulis, E.J. A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J. Surg., 2015, 39(11), 2776-2783.
[http://dx.doi.org/10.1007/s00268-015-3071-z] [PMID: 25894405]
[24]
Dolanbay, S.N.; Aslim, B. Comparison of the anti-carcinogenic effects of some probiotic bacteria and their postbiotics on colorectal cancer cells. Journal of Applied Biological Sciences, 2022, 16(2), 308-325.
[25]
Raman, M.; Ambalam, P.; Kondepudi, K.K.; Pithva, S.; Kothari, C.; Patel, A.T.; Purama, R.K.; Dave, J.M.; Vyas, B.R.M. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes, 2013, 4(3), 181-192.
[http://dx.doi.org/10.4161/gmic.23919] [PMID: 23511582]
[26]
Sultan, S.; Huma, N.; Butt, M.S.; Aleem, M.; Abbas, M. Therapeutic potential of dairy bioactive peptides: A contemporary perspective. Crit. Rev. Food Sci. Nutr., 2018, 58(1), 105-115.
[http://dx.doi.org/10.1080/10408398.2015.1136590] [PMID: 26852912]
[27]
Saez-Lara, M.J.; Gomez-Llorente, C.; Plaza-Diaz, J. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: A systematic review of randomized human clinical trials. Biomed Res. Int., 2015, 2015, 505878.
[http://dx.doi.org/10.1155/2015/505878]
[28]
Bajramagic, S.; Hodzic, E.; Mulabdic, A.; Holjan, S.; Smajlovic, S.; Rovcanin, A. Usage of probiotics and its clinical significance at surgically treated patients sufferig from colorectal carcinoma. Med. Arh., 2019, 73(5), 316-320.
[http://dx.doi.org/10.5455/medarh.2019.73.316-320] [PMID: 31819304]
[29]
Zou, S.; Fang, L.; Lee, M.H. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol. Rep., 2018, 6(1), 1-12.
[http://dx.doi.org/10.1093/gastro/gox031] [PMID: 29479437]
[30]
Collins, D.; Hogan, A.M.; Winter, D.C. Microbial and viral pathogens in colorectal cancer. Lancet Oncol., 2011, 12(5), 504-512.
[http://dx.doi.org/10.1016/S1470-2045(10)70186-8] [PMID: 21067973]
[31]
Antonic, V.; Stojadinovic, A.; Kester, K.E.; Weina, P.J.; Brücher, B.L.D.M.; Protic, M.; Avital, I.; Izadjoo, M. Significance of infectious agents in colorectal cancer development. J. Cancer, 2013, 4(3), 227-240.
[http://dx.doi.org/10.7150/jca.5835] [PMID: 23459622]
[32]
Chong, E.S.L. A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action. World J. Microbiol. Biotechnol., 2014, 30(2), 351-374.
[http://dx.doi.org/10.1007/s11274-013-1499-6] [PMID: 24068536]
[33]
Sałański, P.; Kowalczyk, M.; Bardowski, J.K.; Szczepankowska, A.K. Health-promoting nature of Lactococcus lactis IBB109 and Lactococcus lactis IBB417 strains exhibiting proliferation inhibition and stimulation of Interleukin-18 expression in colorectal cancer cells. Front. Microbiol., 2022, 13(822912), 822912.
[http://dx.doi.org/10.3389/fmicb.2022.822912] [PMID: 35694291]
[34]
Op den Camp, H.J.; Oosterhof, A.; Veerkamp, J.H. Interaction of bifidobacterial lipoteichoic acid with human intestinal epithelial cells. Infect. Immun., 1985, 47(1), 332-334.
[http://dx.doi.org/10.1128/iai.47.1.332-334.1985] [PMID: 3965407]
[35]
Granato, D.; Perotti, F.; Masserey, I.; Rouvet, M.; Golliard, M.; Servin, A.; Brassart, D. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Appl. Environ. Microbiol., 1999, 65(3), 1071-1077.
[http://dx.doi.org/10.1128/AEM.65.3.1071-1077.1999] [PMID: 10049865]
[36]
Mistou, M.Y.; Sutcliffe, I.C.; van Sorge, N.M. Bacterial glycobiology: Rhamnose-containing cell wall polysaccharides in Gram-positive bacteria. FEMS Microbiol. Rev., 2016, 40(4), 464-479.
[http://dx.doi.org/10.1093/femsre/fuw006] [PMID: 26975195]
[37]
Louis, P.; Flint, H.J. Formation of propionate and butyrate by the human colonic microbiota. Environ. Microbiol., 2017, 19(1), 29-41.
[http://dx.doi.org/10.1111/1462-2920.13589] [PMID: 27928878]
[38]
Wierzbicka, A. Mańkowska-Wierzbicka, D.; Mardas, M.; Stelmach-Mardas, M. Role of probiotics in modulating human gut microbiota populations and activities in patients with colorectal cancer—a systematic review of clinical trials. Nutrients, 2021, 13(4), 1160.
[http://dx.doi.org/10.3390/nu13041160] [PMID: 33915854]
[39]
Kraus, S.; Arber, N. Inflammation and colorectal cancer. Curr. Opin. Pharmacol., 2009, 9(4), 405-410.
[http://dx.doi.org/10.1016/j.coph.2009.06.006] [PMID: 19589728]
[40]
Itzkowitz, S.H.; Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287(1), G7-G17.
[http://dx.doi.org/10.1152/ajpgi.00079.2004] [PMID: 15194558]
[41]
Molska, M. Reguła, J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients, 2019, 11(10), 2453.
[http://dx.doi.org/10.3390/nu11102453] [PMID: 31615096]
[42]
Sivaprakasam, S.; Prasad, P.D.; Singh, N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol. Ther., 2016, 164, 144-151.
[http://dx.doi.org/10.1016/j.pharmthera.2016.04.007] [PMID: 27113407]
[43]
Vinolo, M.A.R.; Rodrigues, H.G.; Hatanaka, E.; Sato, F.T.; Sampaio, S.C.; Curi, R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J. Nutr. Biochem., 2011, 22(9), 849-855.
[http://dx.doi.org/10.1016/j.jnutbio.2010.07.009] [PMID: 21167700]
[44]
Oh, N.S.; Joung, J.Y.; Lee, J.Y.; Kim, Y. Probiotic and anti-inflammatory potential of Lactobacillus rhamnosus 4B15 and Lactobacillus gasseri 4M13 isolated from infant feces. PLoS One, 2018, 13(2), e0192021.
[http://dx.doi.org/10.1371/journal.pone.0192021] [PMID: 29444150]
[45]
Zhou, M.; Yuan, W.; Yang, B.; Pei, W.; Ma, J.; Feng, Q. Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway. Ann. Transl. Med., 2022, 10(8), 478.
[http://dx.doi.org/10.21037/atm-22-1670] [PMID: 35571406]
[46]
van Baarlen, P.; Wells, J.M.; Kleerebezem, M. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol., 2013, 34(5), 208-215.
[http://dx.doi.org/10.1016/j.it.2013.01.005] [PMID: 23485516]
[47]
Mager, L.F.; Wasmer, M.H.; Rau, T.T.; Krebs, P. Cytokine-induced modulation of colorectal cancer. Front. Oncol., 2016, 6, 96.
[http://dx.doi.org/10.3389/fonc.2016.00096] [PMID: 27148488]
[48]
Hradicka, P.; Beal, J.; Kassayova, M.; Foey, A.; Demeckova, V. A novel lactic acid bacteria mixture: Macrophage-targeted prophylactic intervention in colorectal cancer management. Microorganisms, 2020, 8(3), 387.
[http://dx.doi.org/10.3390/microorganisms8030387] [PMID: 32168834]
[49]
Yoshii, K.; Hosomi, K.; Sawane, K.; Kunisawa, J. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. Front. Nutr., 2019, 6, 48.
[http://dx.doi.org/10.3389/fnut.2019.00048] [PMID: 31058161]
[50]
Khazaei, M.; Avan, A.; Zafari, N.; Velayati, M.; Damavandi, S.; Pourali, G.; Mobarhan, M.G.; Nassiri, M.; Hassanian, S.M.; Ferns, G.A. Metabolic pathways regulating colorectal cancer: a potential therapeutic approach. Curr. Pharm. Des., 2022, 28(36), 2995-3009.
[http://dx.doi.org/10.2174/1381612828666220922111342] [PMID: 36154599]
[51]
Zeng, H.; Chi, H. Metabolic control of regulatory T cell development and function. Trends Immunol., 2015, 36(1), 3-12.
[http://dx.doi.org/10.1016/j.it.2014.08.003] [PMID: 25248463]
[52]
Mikkelsen, K.; Apostolopoulos, V. Vitamin B1, B2, B3, B5, and B6 and the Immune System. In: Nutrition and immunity; Springer: Berlin, 2019; pp. 115-125.
[http://dx.doi.org/10.1007/978-3-030-16073-9_7]
[53]
Seto, E.; Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol., 2014, 6(4), a018713.
[http://dx.doi.org/10.1101/cshperspect.a018713] [PMID: 24691964]
[54]
Stengel, K.R.; Hiebert, S.W.; Class, I. HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy. Antioxid. Redox Signal., 2015, 23(1), 51-65.
[http://dx.doi.org/10.1089/ars.2014.5915] [PMID: 24730655]
[55]
Kim, H-J.; Bae, S-C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res., 2011, 3(2), 166-179.
[PMID: 21416059]
[56]
Brembeck, F.H.; Rosário, M.; Birchmeier, W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr. Opin. Genet. Dev., 2006, 16(1), 51-59.
[http://dx.doi.org/10.1016/j.gde.2005.12.007] [PMID: 16377174]
[57]
Schneikert, J.; Behrens, J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut, 2007, 56(3), 417-425.
[http://dx.doi.org/10.1136/gut.2006.093310] [PMID: 16840506]
[58]
Luo, J.; Chen, J.; Deng, Z.L.; Luo, X.; Song, W.X.; Sharff, K.A.; Tang, N.; Haydon, R.C.; Luu, H.H.; He, T.C. Wnt signaling and human diseases: what are the therapeutic implications? Lab. Invest., 2007, 87(2), 97-103.
[http://dx.doi.org/10.1038/labinvest.3700509] [PMID: 17211410]
[59]
Munemitsu, S.; Albert, I.; Rubinfeld, B.; Polakis, P. Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. Mol. Cell. Biol., 1996, 16(8), 4088-4094.
[http://dx.doi.org/10.1128/MCB.16.8.4088] [PMID: 8754807]
[60]
Inomata, M.; Ochiai, A.; Akimoto, S.; Kitano, S.; Hirohashi, S. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res., 1996, 56(9), 2213-2217.
[PMID: 8616874]
[61]
Garavaglia, B.; Vallino, L.; Ferraresi, A.; Esposito, A.; Salwa, A.; Vidoni, C.; Gentilli, S.; Isidoro, C. Butyrate inhibits colorectal cancer cell proliferation through autophagy degradation of β-catenin regardless of APC and β-catenin mutational status. Biomedicines, 2022, 10(5), 1131.
[http://dx.doi.org/10.3390/biomedicines10051131] [PMID: 35625868]
[62]
Dikeocha, I.J.; Al-Kabsi, A.M.; Chiu, H.T.; Alshawsh, M.A. Faecalibacterium prausnitzii Ameliorates Colorectal Tumorigenesis And Suppresses Proliferation of HCT116 colorectal cancer cells. Biomedicines, 2022, 10(5), 1128.
[http://dx.doi.org/10.3390/biomedicines10051128] [PMID: 35625865]
[63]
Maroof, H.; Hassan, Z.M.; Mobarez, A.M.; Mohamadabadi, M.A. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J. Clin. Immunol., 2012, 32(6), 1353-1359.
[http://dx.doi.org/10.1007/s10875-012-9708-x] [PMID: 22711009]
[64]
Srikham, K.; Thirabunyanon, M. Bioprophylactic potential of novel human colostrum probiotics via apoptotic induction of colon cancer cells and cell immune activation. Biomed. Pharmacother., 2022, 149, 112871.
[http://dx.doi.org/10.1016/j.biopha.2022.112871] [PMID: 35364380]
[65]
Cousin, F.J.; Jouan-Lanhouet, S.; Théret, N.; Brenner, C.; Jouan, E.; Le Moigne-Muller, G.; Dimanche-Boitrel, M.T.; Jan, G. The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget, 2016, 7(6), 7161-7178.
[http://dx.doi.org/10.18632/oncotarget.6881] [PMID: 26771233]
[66]
Tripathy, A.; Dash, J.; Kancharla, S.; Kolli, P.; Mahajan, D.; Senapati, S.; Jena, M.K. Probiotics: A promising candidate for management of colorectal cancer. Cancers , 2021, 13(13), 3178.
[http://dx.doi.org/10.3390/cancers13133178] [PMID: 34202265]
[67]
Hatakka, K.; Holma, R.; El-Nezami, H.; Suomalainen, T.; Kuisma, M.; Saxelin, M.; Poussa, T.; Mykkänen, H.; Korpela, R. The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon. Int. J. Food Microbiol., 2008, 128(2), 406-410.
[http://dx.doi.org/10.1016/j.ijfoodmicro.2008.09.010] [PMID: 18945506]
[68]
Wang, Y.; Li, H. Gut microbiota modulation: A tool for the management of colorectal cancer. J. Transl. Med., 2022, 20(1), 178.
[http://dx.doi.org/10.1186/s12967-022-03378-8] [PMID: 35449107]
[69]
Kaźmierczak-Siedlecka, K.; Daca, A.; Fic, M.; van de Wetering, T.; Folwarski, M.; Makarewicz, W. Therapeutic methods of gut microbiota modification in colorectal cancer management – fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes, 2020, 11(6), 1518-1530.
[http://dx.doi.org/10.1080/19490976.2020.1764309] [PMID: 32453670]
[70]
Yan, S.; Yang, B.; Zhao, J.; Zhao, J.; Stanton, C.; Ross, R.P.; Zhang, H.; Chen, W. A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation. Food Funct., 2019, 10(3), 1595-1608.
[http://dx.doi.org/10.1039/C9FO00014C] [PMID: 30806428]
[71]
Hsieh, C.Y.; Osaka, T.; Moriyama, E.; Date, Y.; Kikuchi, J.; Tsuneda, S. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol. Rep., 2015, 3(3), e12327.
[http://dx.doi.org/10.14814/phy2.12327] [PMID: 25780093]
[72]
Vachkova, E.; Petrova, V.; Grigorova, N.; Ivanova, Z.; Beev, G. Evaluation of the Anticancer and Probiotic Potential of Autochthonous (Wild) Lacticaseibacillus paracasei Strains from New Ecological Niches as a Possible Additive for Functional Dairy Foods. Foods, 2023, 12(1), 185.
[http://dx.doi.org/10.3390/foods12010185] [PMID: 36613399]
[73]
Pakbin, B.; Allahyari, S.; Dibazar, S.P.; Peymani, A.; Haghverdi, M.K.; Taherkhani, K.; Javadi, M.; Mahmoudi, R. Anticancer properties of saccharomyces boulardii metabolite against colon cancer cells. Probiotics Antimicrob. Proteins, 2022, 2022
[http://dx.doi.org/10.1007/s12602-022-10030-w] [PMID: 36547769]
[74]
Shamekhi, S.; Abdolalizadeh, J.; Ostadrahimi, A.; Mohammadi, S.A.; Barzegari, A.; Lotfi, H.; Bonabi, E.; Zarghami, N. Apoptotic Effect of Saccharomyces cerevisiae on human colon cancer SW480 cells by regulation of Akt/NF-κB signaling pathway. Probiotics Antimicrob. Proteins, 2020, 12(1), 311-319.
[http://dx.doi.org/10.1007/s12602-019-09528-7] [PMID: 30788662]
[75]
Tiptiri-Kourpeti, A.; Spyridopoulou, K.; Santarmaki, V.; Aindelis, G.; Tompoulidou, E.; Lamprianidou, E.E.; Saxami, G.; Ypsilantis, P.; Lampri, E.S.; Simopoulos, C.; Kotsianidis, I.; Galanis, A.; Kourkoutas, Y.; Dimitrellou, D.; Chlichlia, K. Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS One, 2016, 11(2), e0147960.
[http://dx.doi.org/10.1371/journal.pone.0147960] [PMID: 26849051]
[76]
Ranji, P.; Agah, S.; Heydari, Z.; Rahmati-Yamchi, M.; Mohammad Alizadeh, A. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the serum biochemical parameters, and the vitamin D and leptin receptor genes on mice colon cancer. Iran. J. Basic Med. Sci., 2019, 22(6), 631-636.
[PMID: 31231490]
[77]
Rao, C.V.; Sanders, M.E.; Indranie, C.; Simi, B.; Reddy, B.S. Prevention of colonic preneoplastic lesions by the probiotic Lactobacillus acidophilus NCFMTM in F344 rats. Int. J. Oncol., 1999, 14(5), 939-944.
[http://dx.doi.org/10.3892/ijo.14.5.939] [PMID: 10200345]
[78]
Sharaf, L.K.; Sharma, M.; Chandel, D.; Shukla, G. Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. BMC Cancer, 2018, 18(1), 1111.
[http://dx.doi.org/10.1186/s12885-018-4999-9] [PMID: 30424722]
[79]
Limeiras, S.M.A.; Ogo, F.M.; Genez, L.A.L.; Carreira, C.M.; Oliveira, E.J.T.; Pessatto, L.R.; Neves, S.C.; Pesarini, J.R.; Schweich, L.C.; Silva, R.A.; Cantero, W.B.; Antoniolli-Silva, A.C.M.B.; Oliveira, R.J. Prevention of DNA damage and anticarcinogenic activity of Activia® in a preclinical model. Genet. Mol. Res., 2017, 16(1)
[http://dx.doi.org/10.4238/gmr16019492] [PMID: 28340269]
[80]
Budu, O.; Banciu, C.; Pinzaru, I. Sarău, C.; Lighezan, D.; Șoica, C.; Dehelean, C.; Drăghici, G.; Dolghi, A.; Prodea, A.; Mioc, M. A combination of two probiotics, lactobacillus sporogenes and clostridium butyricum, inhibits colon cancer development: An in vitro study. Microorganisms, 2022, 10(9), 1692.
[http://dx.doi.org/10.3390/microorganisms10091692] [PMID: 36144294]
[81]
Baldwin, C.; Millette, M.; Oth, D.; Ruiz, M.T.; Luquet, F.M.; Lacroix, M. Probiotic lactobacillus acidophilus and l. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. Nutr. Cancer, 2010, 62(3), 371-378.
[http://dx.doi.org/10.1080/01635580903407197] [PMID: 20358475]
[82]
Zhuo, Q.; Yu, B.; Zhou, J.; Zhang, J.; Zhang, R.; Xie, J.; Wang, Q.; Zhao, S. Lysates of lactobacillus acidophilus combined with ctla-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model. Sci. Rep., 2019, 9(1), 20128.
[http://dx.doi.org/10.1038/s41598-019-56661-y] [PMID: 31882868]
[83]
Si, W.; Liang, H.; Bugno, J.; Xu, Q.; Ding, X.; Yang, K.; Fu, Y.; Weichselbaum, R.R.; Zhao, X.; Wang, L. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut, 2022, 71(3), 521-533.
[http://dx.doi.org/10.1136/gutjnl-2020-323426] [PMID: 33685966]
[84]
Rodríguez-Padilla, Á.; Morales-Martín, G.; Pérez-Quintero, R.; Gómez-Salgado, J.; Ruiz-Frutos, C. Serological biomarkers and diversion colitis: Changes after stimulation with probiotics. Biomolecules, 2021, 11(5), 684.
[http://dx.doi.org/10.3390/biom11050684] [PMID: 34063276]
[85]
Zhang, J.W.; Du, P.; Yang, B-R.; Gao, J.; Fang, W.J.; Ying, C.M. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am. J. Med. Sci., 2012, 343(3), 199-205.
[http://dx.doi.org/10.1097/MAJ.0b013e31823aace6] [PMID: 22197980]
[86]
Zhu, D.; Xiaowu, C.; Jinhao, W. Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao, 2012, 32(8), 1190-1193.
[87]
Fasano, A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000 Res., 2020, 9, 69.
[http://dx.doi.org/10.12688/f1000research.20510.1] [PMID: 32051759]
[88]
Liu, Z.H.; Huang, M.J.; Zhang, X.W.; Wang, L.; Huang, N.Q.; Peng, H.; Lan, P.; Peng, J.S.; Yang, Z.; Xia, Y.; Liu, W.J.; Yang, J.; Qin, H.L.; Wang, J.P. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am. J. Clin. Nutr., 2013, 97(1), 117-126.
[http://dx.doi.org/10.3945/ajcn.112.040949] [PMID: 23235200]
[89]
Liu, Z.; Li, C.; Huang, M.; Tong, C.; Zhang, X.; Wang, L.; Peng, H.; Lan, P.; Zhang, P.; Huang, N.; Peng, J.; Wu, X.; Luo, Y.; Qin, H.; Kang, L.; Wang, J. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: A double-center and double-blind randomized clinical trial. BMC Gastroenterol., 2015, 15(1), 34.
[http://dx.doi.org/10.1186/s12876-015-0260-z] [PMID: 25881090]
[90]
Lee, J.Y.; Chu, S.H.; Jeon, J.Y.; Lee, M.K.; Park, J.H.; Lee, D.C.; Lee, J.W.; Kim, N.K. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: A double-blind, randomized, placebo-controlled trial. Dig. Liver Dis., 2014, 46(12), 1126-1132.
[http://dx.doi.org/10.1016/j.dld.2014.09.004] [PMID: 25442120]
[91]
Polakowski, C.B.; Kato, M.; Preti, V.B.; Schieferdecker, M.E.M.; Ligocki Campos, A.C. Impact of the preoperative use of synbiotics in colorectal cancer patients: A prospective, randomized, double-blind, placebo-controlled study. Nutrition, 2019, 58, 40-46.
[http://dx.doi.org/10.1016/j.nut.2018.06.004] [PMID: 30278428]
[92]
Golkhalkhali, B.; Rajandram, R.; Paliany, A.S.; Ho, G.F.; Wan Ishak, W.Z.; Johari, C.S.; Chin, K.F. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial. Asia Pac. J. Clin. Oncol., 2018, 14(3), 179-191.
[http://dx.doi.org/10.1111/ajco.12758] [PMID: 28857425]
[93]
Tan, C.K.; Said, S.; Rajandram, R.; Wang, Z.; Roslani, A.C.; Chin, K.F. Pre-surgical administration of microbial cell preparation in colorectal cancer patients: a randomized controlled trial. World J. Surg., 2016, 40(8), 1985-1992.
[http://dx.doi.org/10.1007/s00268-016-3499-9] [PMID: 27098538]
[94]
Mego, M.; Chovanec, J.; Vochyanova-Andrezalova, I.; Konkolovsky, P.; Mikulova, M.; Reckova, M.; Miskovska, V.; Bystricky, B.; Beniak, J.; Medvecova, L.; Lagin, A.; Svetlovska, D.; Spanik, S.; Zajac, V.; Mardiak, J.; Drgona, L. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement. Ther. Med., 2015, 23(3), 356-362.
[http://dx.doi.org/10.1016/j.ctim.2015.03.008] [PMID: 26051570]
[95]
Scartoni, D.; Desideri, I.; Giacomelli, I.; Di Cataldo, V.; Di Brina, L.; Mancuso, A.; Furfaro, I.; Bonomo, P.; Simontacchi, G.; Livi, L. Nutritional supplement based on zinc, prebiotics, probiotics and vitamins to prevent radiation-related gastrointestinal disorders. Anticancer Res., 2015, 35(10), 5687-5692.
[PMID: 26408744]
[96]
Delia, P.; Sansotta, G.; Donato, V.; Frosina, P.; Messina, G.; De Renzis, C.; Famularo, G. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol., 2007, 13(6), 912-915.
[http://dx.doi.org/10.3748/wjg.v13.i6.912] [PMID: 17352022]
[97]
Liu, J.; Huang, X.E. Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac. J. Cancer Prev., 2015, 15(23), 10241-10244.
[http://dx.doi.org/10.7314/APJCP.2014.15.23.10241] [PMID: 25556454]
[98]
Ishikawa, H.; Akedo, I.; Otani, T.; Suzuki, T.; Nakamura, T.; Takeyama, I.; Ishiguro, S.; Miyaoka, E.; Sobue, T.; Kakizoe, T. Randomized trial of dietary fiber andLactobacillus casei administration for prevention of colorectal tumors. Int. J. Cancer, 2005, 116(5), 762-767.
[http://dx.doi.org/10.1002/ijc.21115] [PMID: 15828052]
[99]
Khodaii, Z.; Mehrabani Natanzi, M.; Khalighfard, S.; Ghandian Zanjan, M.; Gharghi, M.; Khori, V.; Amiriani, T.; Rahimkhani, M.; Alizadeh, A.M. Novel targets in rectal cancer by considering lncRNA–miRNA–mRNA network in response to Lactobacillus acidophilus consumption: a randomized clinical trial. Sci. Rep., 2022, 12(1), 9168.
[http://dx.doi.org/10.1038/s41598-022-13297-9] [PMID: 35654932]
[100]
Heydari, Z.; Rahaie, M.; Alizadeh, A.M.; Agah, S.; Khalighfard, S.; Bahmani, S. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and their involving genes in mice colon cancer. Probiotics Antimicrob. Proteins, 2019, 11(4), 1155-1162.
[http://dx.doi.org/10.1007/s12602-018-9478-8] [PMID: 30311185]
[101]
Friederich, P.; Verschuur, J.; van Heumen, B.W.H.; Roelofs, H.M.J.; Berkhout, M.; Nagtegaal, I.D.; van Oijen, M.G.H.; van Krieken, J.H.J.M.; Peters, W.H.M.; Nagengast, F.M. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis. Int. J. Colorectal Dis., 2011, 26(5), 575-582.
[http://dx.doi.org/10.1007/s00384-010-1127-y] [PMID: 21243500]
[102]
Laake, K.O.; Bjørneklett, A.; Aamodt, G.; Aabakken, L.; Jacobsen, M.; Bakka, A.; Vatn, M.H. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand. J. Gastroenterol., 2005, 40(1), 43-51.
[http://dx.doi.org/10.1080/00365520410009339] [PMID: 15841713]
[103]
Morelli, L.; Capurso, L. FAO/WHO guidelines on probiotics: 10 years later. J. Clin. Gastroenterol., 2012, 46(Suppl.), S1-S2.
[http://dx.doi.org/10.1097/MCG.0b013e318269fdd5] [PMID: 22955349]
[104]
Lherm, T.; Monet, C.; Nougière, B.; Soulier, M.; Larbi, D.; Le Gall, C.; Caen, D.; Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med., 2002, 28(6), 797-801.
[http://dx.doi.org/10.1007/s00134-002-1267-9] [PMID: 12107689]
[105]
Hwang, J.B.; Kang, K.J.; Kang, Y.N.; Kim, A.S. Probiotic gastrointestinal allergic reaction caused by Saccharomyces boulardii. Ann. Allergy Asthma Immunol., 2009, 103(1), 87-88.
[http://dx.doi.org/10.1016/S1081-1206(10)60154-8] [PMID: 19663138]
[106]
Mackay, A.D.; Taylor, M.B.; Kibbler, C.C.; Hamilton-Miller, J.M.T. Lactobacillus endocarditis caused by a probiotic organism. Clin. Microbiol. Infect., 1999, 5(5), 290-292.
[http://dx.doi.org/10.1111/j.1469-0691.1999.tb00144.x] [PMID: 11856270]
[107]
Atıcı S.; Soysal, A.; Karadeniz Cerit, K.; Yılmaz, Ş.; Aksu, B.; Kıyan, G.; Bakır, M. Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Med. Mycol. Case Rep., 2017, 15, 33-35.
[http://dx.doi.org/10.1016/j.mmcr.2017.02.002] [PMID: 28280685]
[108]
Haghighat, L.; Crum-Cianflone, N.F. The potential risks of probiotics among HIV-infected persons: Bacteraemia due to Lactobacillus acidophilus and review of the literature. Int. J. STD AIDS, 2016, 27(13), 1223-1230.
[http://dx.doi.org/10.1177/0956462415590725] [PMID: 26130690]
[109]
Hassan, H.; Rompola, M.; Glaser, A.W.; Kinsey, S.E.; Phillips, R.S. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support. Care Cancer, 2018, 26(8), 2503-2509.
[http://dx.doi.org/10.1007/s00520-018-4216-z] [PMID: 29704110]
[110]
Flesch, A.T.; Tonial, S.T.; Contu, P.D.C.; Damin, D.C. Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial. Rev. Col. Bras. Cir., 2017, 44(6), 567-573.
[http://dx.doi.org/10.1590/0100-69912017006004] [PMID: 29267553]

Rights & Permissions Print Cite
Article Metrics
46
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy